

Our Ref: 428/2022

October 2022

## Re: Your request made under the Freedom of Information Act 2000

1 – For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab – Lucentis

Ranibizumab – Ongavia

· Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

2 – For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab – Lucentis

Our Ref: 428/2022

October 2022

Ranibizumab – Ongavia

· Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

3 – How many patients have you treated in the last 12 months with the following drugs?

Genotropin - 3

Humatrope - 0

Norditropin - 3

Nutropin - 0

Omnitrope - 2

Saizen - 1

Zomacton - 0

Any other Somatropin (please specify) - 0